Get in Touch

AKADEUM LIFE SCIENCES TO PRESENT ON EXPANDED PLATFORM AT BIOTECH SHOWCASE™ DIGITAL 2021

Akadeum expands microbubble platform to include an order-of-magnitude improvement to a critical diagnostic testing workflow.

Ann Arbor, Michigan, January 12th, 2021 – Akadeum Life Sciences, today announced that it is participating in Biotech Showcase™. Akadeum has achieved a series of recent scientific advancements and commercial successes through strategic collaborations and aggressive applications discovery. Addressing the needs of the ongoing pandemic, newly developed capabilities include nucleic acid extraction from pooled patient samples to improve sensitivity and throughput of existing molecular diagnostic tests for SARS-CoV-2.

Brandon McNaughton, Akadeum CEO and co-founder, is highlighting how Akadeum’s proprietary microbubbles are impacting the continuum of human health science by benefiting processes from research to diagnostics and therapeutics.

Target isolation of cells, nucleic acids, proteins, and other biomolecules is essential to biotech workflows. Today, this critical step of isolation is hampered by harsh, ineffective, and unnecessarily complex sample preparation. Akadeum’s microbubble technology enables a quantum leap in process capabilities. Simple, fast, automatable, and inexpensive—the microbubble protocols use inherent buoyancy to engage and isolate biological targets in a gentle manner, permitting high throughput and large-scale processes in cell therapy, liquid biopsy, and research.

“Given Akadeum’s strong results in 2020, we are looking forward to Biotech Showcase as we expand our Partnerships, grow commercialization efforts, and invest in advanced automation offerings,” said McNaughton.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Akadeum will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”




ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT AKADEUM LIFE SCIENCES
Akadeum is a private early-stage life sciences company based in Ann Arbor, MI. Founded in 2014, Akadeum was established with the goal of advancing human health. Akadeum creates advanced isolation products and fundamentally changes the way that isolating chemical and biological targets is approached. Akadeum’s goal is to enable entirely new assays and workflows by delivering a microbubble platform technology that can isolate any sample, any volume, anywhere.

Key Takeaways
  • Akadeum Life Sciences, today announced that it is participating in Biotech Showcase™.
  • Akadeum has achieved a series of recent scientific advancements and commercial successes through strategic collaborations and aggressive applications discovery.
  • Addressing the needs of the ongoing pandemic, newly developed capabilities include nucleic acid extraction from pooled patient samples to improve sensitivity and throughput of existing molecular diagnostic tests for SARS-CoV-2.
Media Gallery
Video Gallery
Akadeum Microbubbles for Cell Depletion
View on Vimeo
Quotes
Given Akadeum’s strong results in 2020, we are looking forward to Biotech Showcase as we expand our Partnerships, grow commercialization efforts, a...
Brandon H. McNaughton, Ph.D.CEO and Co-founder
Related Bios
Brandon H. McNaughton, Ph.D.
CEO and Co-founder
View Full Bio>>
Contacts
Akadeum Inquiries
info@akadeum.com